Tenaya Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 70

Employees

  • Stock Symbol
  • TNYA

Stock Symbol

  • Share Price
  • $0.29
  • (As of Friday Closing)

Tenaya Therapeutics General Information

Description

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 171 Oyster Point Boulevard
  • Suite 500
  • South San Francisco, CA 94080
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 171 Oyster Point Boulevard
  • Suite 500
  • South San Francisco, CA 94080
  • United States
+1 (415)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tenaya Therapeutics Stock Performance

As of 20-Nov-2026, Tenaya Therapeutics’s stock price is $0.29. Its current market cap is $65.3M with 228M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.29 $0.30 $0.28 - $1.46 $65.3M 228M 2.93M -$0.49

Tenaya Therapeutics Financials Summary

As of 30-Sep-2026, Tenaya Therapeutics has a trailing 12-month revenue of $3.03M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 61,209 109,259 48,354 110,971
Revenue 3,032 0 0 0
EBITDA (98,797) (84,843) (107,398) (122,440)
Net Income (101,778) (90,597) (111,129) (124,084)
Total Assets 76,681 146,921 119,940 170,515
Total Debt 2,852 10,830 13,608 12,424
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tenaya Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tenaya Therapeutics‘s full profile, request access.

Request a free trial

Tenaya Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Tenaya Therapeutics‘s full profile, request access.

Request a free trial

Tenaya Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies
Drug Discovery
South San Francisco, CA
70 As of 2025

Cranbury, NJ
 

West Conshohocken, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tenaya Therapeutics Competitors (56)

One of Tenaya Therapeutics’s 56 competitors is Rocket Pharmaceuticals, a Formerly VC-backed company based in Cranbury, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rocket Pharmaceuticals Formerly VC-backed Cranbury, NJ
Madrigal Pharmaceuticals Formerly VC-backed West Conshohocken, PA
Regenxbio Formerly VC-backed Rockville, MD
uniQure Formerly VC-backed Amsterdam, Netherlands
Sharp Therapeutics (Biotechnology) Formerly VC-backed Pittsburgh, PA
You’re viewing 5 of 56 competitors. Get the full list »

Tenaya Therapeutics Patents

Tenaya Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026165422-A1 Rbm20 gene editing systems and methods of use Pending 31-Jan-2025
WO-2026156172-A2 Biomarkers in arrhythmogenic right ventricular cardiomyopathy and methods of treatment Pending 16-Jan-2025
WO-2026122463-A1 Adeno-associated virus with engineered capsid Pending 02-Dec-2024
WO-2026080860-A1 Prime editing compositions and methods of use Pending 11-Oct-2024
WO-2026080685-A1 Guide rnas, vectors, and virions for targeting mutations in the pln gene Pending 10-Oct-2024 C12N15/86
To view Tenaya Therapeutics’s complete patent history, request access »

Tenaya Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tenaya Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Tenaya Therapeutics‘s full profile, request access.

Request a free trial

Tenaya Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.02 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Tenaya Therapeutics’s complete esg history, request access »

Tenaya Therapeutics FAQs

  • When was Tenaya Therapeutics founded?

    Tenaya Therapeutics was founded in 2016.

  • Where is Tenaya Therapeutics headquartered?

    Tenaya Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of Tenaya Therapeutics?

    Tenaya Therapeutics has 70 total employees.

  • What industry is Tenaya Therapeutics in?

    Tenaya Therapeutics’s primary industry is Drug Discovery.

  • Is Tenaya Therapeutics a private or public company?

    Tenaya Therapeutics is a Public company.

  • What is Tenaya Therapeutics’s stock symbol?

    The ticker symbol for Tenaya Therapeutics is TNYA.

  • What is the current stock price of Tenaya Therapeutics?

    As of 20-Nov-2026 the stock price of Tenaya Therapeutics is $0.29.

  • What is the current market cap of Tenaya Therapeutics?

    The current market capitalization of Tenaya Therapeutics is $65.3M.

  • What is Tenaya Therapeutics’s current revenue?

    The trailing twelve month revenue for Tenaya Therapeutics is $3.03M.

  • Who are Tenaya Therapeutics’s competitors?

    Rocket Pharmaceuticals, Madrigal Pharmaceuticals, Regenxbio, uniQure, and Sharp Therapeutics (Biotechnology) are some of the 56 competitors of Tenaya Therapeutics.

  • What is Tenaya Therapeutics’s annual earnings per share (EPS)?

    Tenaya Therapeutics’s EPS for 12 months was -$0.49.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process